TOI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oncology Institute Inc (TOI) does not present a strong buy opportunity at this time for a beginner investor with a long-term strategy. While the stock shows some positive technical indicators and analyst optimism, the lack of significant recent news, hedge fund selling trends, and no proprietary trading signals suggest holding off on immediate investment.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), a positive MACD histogram (0.0122), and RSI_6 at 64.327, indicating a neutral zone. The price is trading near its pivot level of 5.072, with resistance at 5.46 and 5.699, and support at 4.684 and 4.445.
Analyst optimism with a raised price target to $7 and a Buy rating, citing potential growth from increased pharmacy volume and capitated contracts. The technical indicators also show a bullish trend.
Hedge funds are selling heavily, with a 47487.34% increase in selling over the last quarter. No significant insider trading trends or recent news to drive momentum. No proprietary trading signals are present.
No financial data available for the latest quarter.
Needham raised the price target to $7 from $5 and maintains a Buy rating, citing positive developments in pharmacy volume and contract pipeline growth.
